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Temporomandibular jointAbstract Temporomandibular joint (TMJ) ankylosis can restrict the mandibular movement, fol-
lowed by resulting in numerous problems. To understand the mechanism of TMJ ankylosis (TMJA)
and prevent the generation of TMJA is urgent necessary. Although many factors contribute to it,
trauma is the most common cause of TMJA. The mechanisms of TMJA are still unclear, and the dis-
traction osteogenesis of the lateral pterygoid muscle (LPM) may play an important role. Injection of
very small amounts of botulinum toxin type A (BTA) can temporarily block the muscle’s impulse and
has been revealed to be an effective treatment method for many temporomandibular disorders. In this
article, we make a hypothesis that LPM injection of BTA as a novel method for immobilization of
mandible, followed by preventing the traumatic TMJA.Furthermore, the side effects of local injection
of BTA also are minimal, temporary, reversible and self-limiting. If this strategy is validated, LPM
injection of BTA will be a cost effective way to be administrated to prevent the traumatic TMJA.
ª 2014 Tehran University of Medical Sciences. Published by Elsevier Ltd. All rights reserved.Introduction
The position and intricate arrangement get the temporoman-
dibular joint (TMJ) to be susceptible to injury during traumaticepisodes such as rear-end collisions involving cervical whiplash
and other blows to the face [1]. The TMJ can be affected by
trauma in a number of ways such as condylar process fractures,
TMJ dislocation and fracture of the mandibular fossa [1].
6 J. Dai et al.The treatment methods of condylar process fractures have gen-
erated a great deal of discussion and controversy [2]. Many dif-
ferent methods, including open surgery, conservative and
closed reduction by inter-maxillary ﬁxation or splints, are
applied to treat it [3,4]. For closed reduction, a 10-day period
of inter-maxillary ﬁxation to regain normal occlusion relation-
ship and a functional mobilization schedule for three weeks is
necessary. For open surgery, except for the inter-maxillary ﬁx-
ation in the ﬁrst few days after surgery, the lateral pterygoid
muscle (LPM) should be preserved because anatomic reduction
of the dislocated condyle and LPM is more favorable than the
liberation reduction of the fractured condyle which peeled off
LPM, which may attribute to the blood supply of LPM to pre-
vent the absorption of condyle. Unfortunately, there will be
probability to cause traumatic TMJ ankylosis (TMJA) regard-
less of treatment method. TMJA is an intracapsular union of
the disc-condyle complex to the temporal articular surface
which restricts mandibular movements [5]. It may cause a great
deal of problems in mastication, digestion, speech, breath,
appearance and hygiene [6]. The mechanisms of traumatic
TMJA are still unclear. The existing hypothesis is the organiza-
tion and ossiﬁcation of an intracapsular hematoma following
the TMJ injury contribute to it. However, this hypothesis has
not been conﬁrmed [6,7]. Now, A study hypothesizes that the
distraction osteogenesis (DO) of the LPM combining with the
dislocated and damaged disc is an important factor for causing
traumatic TMJA [8]. Several researches have also supported
this hypothesis. A study based on the model animal showed
that there was hyperplasia of new bone between the fragment
and lateral stump of the condyle in sheep model which similar
to clinical cases [9], and when DO of the LPMwas interfered by
proper treatment, such as using open-mouth plate to maintain
mandibular position in the positive mouth opening in which the
LPM was relaxed, or open reduction and internal ﬁxation by
which the fragment was repositioned and ﬁxed, almost normal
condylar shape would be observed after the fracture healing
[10]. Based on these ﬁnds, we can hypotheses that restricting
the contraction of LPM may restrict the mandible mobiliza-
tion, what most important is it may be a method for prevention
of traumatic TMJA. So ﬁnding a suitable strategy to restrict theFig. 1 Diagrammatic representation of the hypothesis. Trauma woul
osteogenesis of the lateral pterygoid muscle during the healed process m
We make a hypothesis that lateral pterygoid muscle injection of bo
mandible, followed by preventing the traumatic temporomandibular jfunction of LPM at early stage after trauma or surgery, and is
reversible at later stage, is urgently necessary.
Hypothesis
Botulinum toxin type A (BTA) are puriﬁed substances that
derived from clostridium botulinum, and can block muscular
nerve signals. Injection of very small amounts of BTA into spe-
ciﬁc facial muscles can block the muscle’s impulse and tempo-
rarily weakens the contraction of muscle [11]. Botulinum toxin
has been used since 1980 to treat many muscle disorders such
as lazy eye and uncontrolled blinking. It was pioneered by der-
matologic surgeons for cosmetic use in 1987. Now, BTA has
been extensively used for treatment of blepharospasm, hemifa-
cial spasm, strabismus, oromandibular dystonia, spasmodic
torticollis, and spasmodic dysphonia [12]. Several studies also
show that local muscle injection of BTA, including lateral pter-
ygoid, masseter, medial pterygoid, temporalis and et al., is
effective treatment for temporomandibular disorders [13,14].
Additionally, a recent study revealed that intramuscular injec-
tion of botulinum toxin as an adjunct to total joint replace-
ment in temporomandibular joint ankylosis [15]. In this
article, we hypothesize that LPM injection of BTA is a novel
method for mandible immobilization, followed by inhibiting
DO and preventing of traumatic TMJA. The diagrammatic
representation of the hypothesis was showed in Fig. 1.
Patients with condylar fracture could be chosen for injection
of BTA. LPM injection of BTA can be applied 2–3 days after
intermaxillary ﬁxation in closed reduction or after open surgery
for TMJ trauma being performed. As these patients receive dif-
ferent drugs, doctors should consider drug interaction like ami-
noglycosides, cyclosporine, D-penicillamine, muscle relaxants,
aminoquinolones, quinidine, magnesium sulfate, and lincosa-
mide. Additionally, doctors also should consider contraindica-
tions of botox like hypersensitivity to botox, human albumin
and pregnancy. A recommend dose is 5–10 units per time,
and some studies also suggested a dose of 20–40 units per time.
The dose of BTA is individualized to the patient, and many
other factors such as muscle size and activity should also be
taken into consideration. A 30-gauge needle is preferable andd lead to injured condylar bone and cartilage. Then the distraction
ay contribute to the traumatic temporomandibular joint ankylosis.
tulinum toxin type A as a novel method for immobilization of
oint ankylosis ankylosis.
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injection is always helpful. There are variations of these basic
techniques for local injection and considerable caution should
be taken while injecting in fratemporal fossa area where sur-
rounded by the pterygoid plexus of veins. Take the extraoral
approach for example [16,17], we should ﬁrstly conﬁrm the
location of the condylar process by palpation when the patient
demonstrates mandibular motion and can use the electromyog-
raphy (ECG) guidance for the injection. Of course, we should
be careful for some patients since the anatomy of the condyle
will be disturbed post-trauma. The needle is advanced at 45
posteriorly to gently engage the condylar process when inserted
through the skin in the coronoid notch area. Then withdraw
slightly and advance more anteriorly and slightly deeper to
reach the proper position. Finally, aspiration and injection
are performed. Regular follow-up for patients also is necessary,
and the follow-up process at least sustain half a year. Doctors
need to periodical (once every two weeks) test the function of
lateral pterygoid muscle and temporomandibular joint to
decide whether need to repeat the injection of BTA for some
patients, or need some further therapy such as open mouth
training and physiotherapy. In addition, due to infection could
also induce joint ankylosis formation, we should carefully
examine the patients to exclude infection related cases during
this treatment procedure. Furthermore, for some patients
who have previous history of BTA injection, we should take
the decreased effect due to the production of antibodies into
consideration.
Testing the hypothesis
The following research directions are recommended to test our
hypothesis:
1. Building a traumatic temporomandibular joint ankylosis
goat model.
2. Performing injection of botulinum toxin type A in lateral
pterygoid muscle as a novel method for immobilization of
mandible to prevent the traumatic temporomandibular
joint ankylosis in this goat model, and observing the effect
based on Micro CT, H&E staining and general observation.
Discussion
Trauma is the most common cause of TMJA which leads to
many problems and its treatment is difﬁcult. Management of
TMJA is mainly through surgical intervention, but the results
were variable and often were not satisfactory [2,18]. Prevention
of traumatic ankylosis is urgently necessary, but always unre-
solved due to its unclear mechanisms. Based on the possible
mechanism that the DO of the LPM is an important factor
in causing traumatic TMJA, we suggest that LPM injection
of BTA as a novel method for prevention of traumatic TMJA.
The LPM acts to lower the mandible and is also essential in
pulling the capsule and disc forward during mouth opening,
thereby maintaining normal relationship between the TMJ disc
and condyle [19]. So local injection of BTA can help to immo-
bilize mandible and keep the TMJ disc in a normal position at
early stage. A functional mobilization for three weeks after a
10-day period of intermaxillary ﬁxation will begin, and theparalysis of LPM will not affect the passive mouth opening
exercise and masticate function due to the assistance by the
digastric, mylohyoid and geniohyoid muscles. The effect of
BTA can last about 4 months which is similar to the length
of the time for a bone fracture to heal [11,20]. So the condylar
fractures will have well healed and do not to cause ankylosis
when the contraction function of LPM reverse. In addition,
side effects of local injection of BTA are generally minimal,
temporary, reversible, and self-limiting [21]. What most impor-
tant is the BTA has been demonstrated that is effective treat-
ment methods for temporomandibular disorders and the
LPM injection are mature techniques, especially by the guid-
ance of ECG. Compared to local anesthetic by lidocaine which
need repeat injection many times due to it sustains a short
time, injection of BTA once may be enough and the medical
costs and infection risk greatly reduced. If this strategy is val-
idated, the prevention of traumatic TMJ ankylosis will become
reality, ﬁnally bring great hope to patients with TMJ trauma.Overview Box.First Question: What do we already know about the
subject?The mechanisms of traumatic temporomandibular
joint ankylosis are still unclear, and the distraction
osteogenesis of the lateral pterygoid muscle may play
an important role. Injection of very small amounts of
botulinum toxin A can temporarily block the muscle’s
impulse and has been revealed that is an effective treat-
ment method for many temporomandibular disorders.
Additionally, a recent study revealed that intramuscu-
lar injection of botulinum toxin as an adjunct to total
joint replacement in temporomandibular joint ankylo-
sis. Furthermore, the side effects of local injection of
botulinum toxin A also are minimal, temporary,
reversible and self-limiting. These ﬁnds implied that
lateral pterygoid muscle injection of botulinum toxin
type A may be a novel method for immobilization of
mandible, followed by preventing the traumatic tem-
poromandibular joint ankylosis.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
If this strategy is validated, lateral pterygoid muscle
injection of botulinum toxin A will be a cost effective
way that may be administrated to prevent traumatic
ankylosis.
Third Question: Among numerous available studies,
what special further study is proposed for testing the
idea?
In order to evaluate the hypothesis, studies that build-
ing a traumatic temporomandibular joint ankylosis
goat model is necessary. Then perform injection of
botulinum toxin type A in lateral pterygoid muscle as
a novel method for immobilization of mandible to pre-
vent the traumatic temporomandibular joint ankylosis
in this goat model, and observing the effect based on
Micro CT, H&E staining and general observation.
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